Viola W. Zhu

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study”.

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The Lancet Diabetes & Endocrinology(2021)10.1016/s2213-8587(21)00120-0

N/A

5.1DataRank · unranked

354 citations

Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano +20 more

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study

Thyroid(2023)10.1089/thy.2023.0363

N/A

1.2DataRank · unranked

55 citations

Mimi I. Hu, Aaron S. Mansfield, Matthew H. Taylor, Martin Schüler, Viola W. Zhu +19 more

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

JTO Clinical and Research Reports(2022)10.1016/j.jtocrr.2022.100427

N/A

0DataRank · unranked

12 citations

Shuai Chen, Joanna B. Eldredge, Shiruyeh Schokrpur, Debory Li, Zhikuan Quan +11 more

Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.05.021

N/A

0DataRank · unranked

73 citations

Victoria M. Raymond, Richard B. Lanman, Jacqulyne Robichaux, Junqin He, Monique B. Nilsson +17 more

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0231

N/A

0DataRank · unranked

49 citations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson +23 more

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100187

N/A

0DataRank · unranked

33 citations

Jaime L. Schneider, Tejas Patil, Viola W. Zhu, Debra A. Goldman, Soo-Ryum Yang +13 more

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.02.004

N/A

0DataRank · unranked

57 citations

Christian Rolfo, Alexander Drilon, Mario E. Lacouture, Benjamin Besse, Kōichi Goto +10 more